Almirall and Evotec to collaborate on multiple severe skin disease targets

A new dermatological alliance between Spanish skin health firm Almirall and German-listed Evotec aims to discover new drugs for the treatment of skin diseases including cancers and eczema.

Photo: Almirall / PR

A new dermatological multi-target alliance was established on Thursday, as Almirall and Evotec join forces to discover new treatments for a variety of skin diseases, Almirall has announced in a press release.

The firms will aim to develop new therapies against severe skin diseases, ”including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma,” the statement reads.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs